209 related articles for article (PubMed ID: 17599426)
1. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Ginsberg HN; Bonds DE; Lovato LC; Crouse JR; Elam MB; Linz PE; O'connor PJ; Leiter LA; Weiss D; Lipkin E; Fleg JL;
Am J Cardiol; 2007 Jun; 99(12A):56i-67i. PubMed ID: 17599426
[TBL] [Abstract][Full Text] [Related]
2. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Goff DC; Gerstein HC; Ginsberg HN; Cushman WC; Margolis KL; Byington RP; Buse JB; Genuth S; Probstfield JL; Simons-Morton DG;
Am J Cardiol; 2007 Jun; 99(12A):4i-20i. PubMed ID: 17599424
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Cushman WC; Grimm RH; Cutler JA; Evans GW; Capes S; Corson MA; Sadler LS; Alderman MH; Peterson K; Bertoni A; Basile JN;
Am J Cardiol; 2007 Jun; 99(12A):44i-55i. PubMed ID: 17599425
[TBL] [Abstract][Full Text] [Related]
4. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
5. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
Betteridge J
Am J Med; 2005 Dec; 118 Suppl 12A():10-5. PubMed ID: 16356802
[TBL] [Abstract][Full Text] [Related]
6. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
7. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Cheng AY; Leiter LA
Curr Opin Cardiol; 2006 Jul; 21(4):400-4. PubMed ID: 16755211
[TBL] [Abstract][Full Text] [Related]
8. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials and lipid guidelines for type II diabetes.
Prisant LM
J Clin Pharmacol; 2004 Apr; 44(4):423-30. PubMed ID: 15051751
[TBL] [Abstract][Full Text] [Related]
10. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
[TBL] [Abstract][Full Text] [Related]
11. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Bonds DE; Kurashige EM; Bergenstal R; Brillon D; Domanski M; Felicetta JV; Fonseca VA; Hall K; Hramiak I; Miller ME; Osei K; Simons-Morton DG;
Am J Cardiol; 2007 Jun; 99(12A):80i-89i. PubMed ID: 17599428
[TBL] [Abstract][Full Text] [Related]
12. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.
; Buse JB; Bigger JT; Byington RP; Cooper LS; Cushman WC; Friedewald WT; Genuth S; Gerstein HC; Ginsberg HN; Goff DC; Grimm RH; Margolis KL; Probstfield JL; Simons-Morton DG; Sullivan MD
Am J Cardiol; 2007 Jun; 99(12A):21i-33i. PubMed ID: 17599422
[TBL] [Abstract][Full Text] [Related]
13. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
Jones PH
Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
[TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
Sever PS
Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
[TBL] [Abstract][Full Text] [Related]
15. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
Steinmetz A
Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
[TBL] [Abstract][Full Text] [Related]
16. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Kingry C; Bastien A; Booth G; Geraci TS; Kirpach BR; Lovato LC; Margolis KL; Rosenberg Y; Sperl-Hillen JM; Vargo L; Williamson JD; Probstfield JL;
Am J Cardiol; 2007 Jun; 99(12A):68i-79i. PubMed ID: 17599427
[TBL] [Abstract][Full Text] [Related]
17. Combination statin-fibrate therapy: safety aspects.
Franssen R; Vergeer M; Stroes ES; Kastelein JJ
Diabetes Obes Metab; 2009 Feb; 11(2):89-94. PubMed ID: 18518891
[TBL] [Abstract][Full Text] [Related]
18. Interpreting clinical trials of diabetic dyslipidaemia: new insights.
Wierzbicki AS
Diabetes Obes Metab; 2009 Mar; 11(3):261-70. PubMed ID: 17645560
[TBL] [Abstract][Full Text] [Related]
19. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
Sampalis JS; Bissonnette S; Habib R; Boukas S;
Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
[TBL] [Abstract][Full Text] [Related]
20. Do people with diabetes need statins?
White JR
Diabetes Educ; 2008; 34(4):664-73. PubMed ID: 18669808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
